One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System
- PMID: 21393043
- PMCID: PMC3095751
- DOI: 10.1016/j.ijid.2011.02.002
One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System
Abstract
Background: While studies have demonstrated higher medium-term mortality for community-acquired pneumonia (CAP), mortality and costs have not been characterized for healthcare-associated pneumonia (HCAP) over a 1-year period.
Methods: We conducted a retrospective cohort study to evaluate mortality rates and health system costs for patients with CAP or HCAP during initial hospitalization and for 1 year after hospital discharge. We selected 50 758 patients admitted to the Veterans Affairs (VA) healthcare system between October 2003 and May 2007. Main outcome measures included hospital, post-discharge, and cumulative mortality rates and cost during initial hospitalization and at 12 months following discharge.
Results: Hospital and 1-year HCAP mortality were nearly twice that of CAP. HCAP was an independent predictor for hospital mortality (odds ratio (OR) 1.62, 95% confidence interval (CI) 1.49-1.76) and 1-year mortality (OR 1.99, 95% CI 1.87-2.11) when controlling for demographics, comorbidities, pneumonia severity, and factors associated with multidrug-resistant infection, including immune suppression, previous antibiotic treatment, and aspiration pneumonia. HCAP patients consistently had higher mortality in each stratum of the Charlson-Deyo-Quan comorbidity index. HCAP patients incurred significantly greater cost during the initial hospital stay and in the following 12 months. Demographics and comorbid conditions, particularly aspiration pneumonia, accounted for 19-33% of this difference.
Conclusion: HCAP represents a distinct category of pneumonia with particularly poor survival up to 1 year after hospital discharge. While comorbidities, pneumonia severity, and risk factors for multidrug-resistant infection may interact to produce even higher mortality compared to CAP, they alone do not explain the observed differences.
Copyright © 2011 International Society for Infectious Diseases. All rights reserved.
Conflict of interest statement
No conflicts exist for any of the authors.
Figures
References
-
- Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57(14):1–134. [PMID: 19788058] - PubMed
-
- Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20(4):820–837. [PMID: 9737840] - PubMed
-
- Ewing S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis. 2010;10:279–287. - PubMed
-
- American Thoracic Society and the Infectious Disease Society of America Documents. Niederman MS, Craven DE Co-chairs. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health-care-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
